reamberin and Tuberculosis--Pulmonary

The efficacy ofreamberin, remaxol, S-adenosyl-L-methionine (ademethionine) and 5% glucose solution was estimated in the treatment of patients with tuberculosis of the respiratory organs and drug hepatotoxicity signs confirmed by higher activity of liver indicative enzymes and nitrogen oxide levels. Remaxol showed a pronounced positive effect on the cytolytic syndrome signs, evident from lower activity of alanine aminotransferase and aspartate aminotransferase. At the same time ademethionine was superior to remaxol in the effect on the cholestatic signs and inferior in the effect on the cytolytic signs. By the effect on the activity of alanine aminotransferase and aspartate aminotransferase, reamberin was inferior to remaxol and superior to ademe-thionine, its effect on the cholestasis markers level vs. the other drugs being superior only to that of 5% glucose solution. As compared to reamberin, ademethionine and 5% glucose solution, remaxol promoted higher integral indices of the host antioxidant protection (total antioxidant capacity and total antioxidant status), that partially explained the drug pronounced hepatoprotective effect.

Topics: Adolescent; Adult; Alanine Transaminase; Aspartate Aminotransferases; Chemical and Drug Induced Liver Injury; Female; Humans; Male; Meglumine; Middle Aged; S-Adenosylmethionine; Succinates; Tuberculosis, Pulmonary

The use of reamberin for prophylaxis of side effects was estimated in 257 patients with tuberculosis of the respiratory organs under the chemotherapy. The reference group involved 241 patients treated with the chemotherapeutics alone. Reamberin in the treatment of the patients, including subjects with multidrug resistant Mycobacterium tuberculosis, promoted a 2-fold decrease in the frequency of the intoxication syndrome during the first month of the treatment. Adverse reactions (toxic, allergic) to the antituberculosis chemotherapeuties were 2.4 times less frequent in the patients additionally treated with reamberin. Positive effect of reamberin on the activity of AIAT and AsAT was observed, the effect being higher, when the pathogen was susceptible to the drugs.

Topics: Adult; Antitubercular Agents; Chemical and Drug Induced Liver Injury; Drug Resistance, Multiple, Bacterial; Female; Humans; Male; Meglumine; Middle Aged; Mycobacterium tuberculosis; Succinates; Tuberculosis, Pulmonary

The effect of the drug "Reamberin" cytotoxic activity of natural killer cells (EC) in an experimental model in the blood samples of patients with pulmonary tuberculosis and healthy donors. Simulation acute systemic inflammation by adding to the culture medium of BCG. After 48 hours, selection was performed mononuclear peripheral blood by gradient centrifugation tests set cytotoxic tumor cell line K-562. Revealed the stimulating effect of the drug "Reamberin" cytotoxic activity of natural killer cells. Metabolic Correction has had a positive impact on the energy metabolism of blood natural killer cells, to increase their survial and cytotoxicity.

Topics: Adult; Humans; Immunity, Cellular; K562 Cells; Killer Cells, Natural; Male; Meglumine; Mycobacterium bovis; Succinates; Tuberculosis, Pulmonary

To comparatively evaluate the hepatoprotective activity of reamberine, remaxol, and exogenous ademethionine and a risk for unfavorable/favorable outcomes of their use in patients with liver injury during antituberculosis chemotherapy.. One hundred and eighty patients with new-onset respiratory tuberculosis were examined and divided into 4 groups (45 patients in each group): Study Group 1 (SG1): patients who took reamberine; Study Group 2 (SG2): those who received remaxol; Study Group 3 (SG3): those who had ademethionine; and a Comparative Group (CG): those who received 5% glucose solution. The test drugs were intravenously administered in a dropwise manner once daily for 10 days. The laboratory hepatic injury severity index (LHISI) was estimated according to the method described by T.N. Kalachnyuk and the risk for a favorable/unfavorable outcome was assessed, by calculating the average cost of the used hepatotropic agents.. LHISI increased statistically significantly with the development of liver injury induced by antituberculosis agents. There was a statistically significant reduction in LHISI during therapy with the test hepatotropic agents versus glucose solution, the most pronounced activity being shown by remaxol. Relative risk (RR) and odds ratio (OR) assessments revealed the high likelihood of a favorable outcome (a reduction in LHISI) when each of the 3 test drugs versus glucose solution was administered; the highest RR and OR were also found in the use of remaxol. Estimation of costs and the number of patients to be treated (NPBT) in order to avoid a case of none LHLIS reduction could reveal the highest efficacy of remaxol.. The test agents (reamberine, remaxol, and ademethionine) are effective in treating tuberculosis patients with drug-induced liver injury. The administration of remaxol demonstrated the highest positive effect (as estimated by LHISI) in terms of both RR and NPBT.

Topics: Adult; Antitubercular Agents; Chemical and Drug Induced Liver Injury; Drug Costs; Humans; Meglumine; Numbers Needed To Treat; Protective Agents; Risk Assessment; S-Adenosylmethionine; Severity of Illness Index; Succinates; Treatment Outcome; Tuberculosis, Pulmonary